We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+15.33%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$294M
AUM Growth
+$106M
Cap. Flow
+$106M
Cap. Flow %
35.98%
Top 10 Hldgs %
58.58%
Holding
91
New
29
Increased
26
Reduced
8
Closed
19

Top Buys

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$27.6M
2
ARYD
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
+$7.56M
3
TVTX icon
Travere Therapeutics
TVTX
+$6.08M
4
MORF
Morphic Holding, Inc. Common Stock
MORF
+$5.85M
5
NAUT icon
Nautilus Biotechnolgy
NAUT
+$5.39M

Top Sells

Rank Stock Value
1
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
+$29.6M
2
CRIS icon
Curis
CRIS
+$4.71M
3
STRO icon
Sutro Biopharma
STRO
+$2.85M
4
ATNX
Athenex, Inc. Common Stock
ATNX
+$2.21M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$2.2M

Sector Composition

Rank Sector Weight
1 Healthcare 63.48%
2 Financials 2.49%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$43.6M 14.81%
110,000
+70,000
+175% +$27M
BBIO icon
2
BridgeBio Pharma
BBIO
$15.9B
$35.6M 12.08%
577,500
+422,500
+273% +$27.6M
ARKG icon
3
PUT
ARK Genomic Revolution ETF
ARKG
$1.61B
$21.3M 7.23%
240,000
+200,000
+500% +$19.8M
MORF
4
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$12.3M 4.19%
195,000
+127,500
+189% +$5.85M
CRIS icon
5
Curis
CRIS
$9.02M
$11.3M 3.84%
2,500
-1,125
-31% -$4.71M
VRTX icon
6
CALL
Vertex Pharmaceuticals
VRTX
$123B
$10.7M 3.65%
+50,000
New +$11M
VINC
7
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$10.5M 3.56%
27,151
+7,001
+35% +$2.82M
KURA icon
8
Kura Oncology
KURA
$964M
$10.3M 3.5%
365,000
+105,000
+40% +$3.32M
NAUT icon
9
Nautilus Biotechnolgy
NAUT
$221M
$9.49M 3.22%
689,000
+389,000
+130% +$5.39M
ARYD
10
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$7.33M 2.49%
+700,000
New +$7.56M
XLRN
11
DELISTED
Acceleron Pharma
XLRN
$6.1M 2.07%
45,000
– –
ACRS icon
12
Aclaris Therapeutics
ACRS
$793M
$5.6M 1.9%
+222,267
New +$4.35M
TVTX icon
13
Travere Therapeutics
TVTX
$5.27B
$5.49M 1.87%
+220,000
New +$6.08M
NARI
14
DELISTED
Inari Medical, Inc. Common Stock
NARI
$5.35M 1.82%
50,000
+40,000
+400% +$4.15M
SNDX icon
15
CALL
Syndax Pharmaceuticals
SNDX
$2.02B
$4.26M 1.45%
190,500
+40,000
+27% +$904K
SNCE
16
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$4.06M 1.38%
20,000
+5,000
+33% +$1.09M
RCKT icon
17
Rocket Pharmaceuticals
RCKT
$376M
$3.77M 1.28%
85,000
-20,000
-19% -$1.1M
OCUL icon
18
Ocular Therapeutix
OCUL
$1.96B
$3.73M 1.27%
227,500
+7,500
+3% +$144K
CERE
19
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$3.71M 1.26%
270,000
– –
ALDX icon
20
Aldeyra Therapeutics
ALDX
$102M
$3.56M 1.21%
300,000
+200,000
+200% +$2.3M
ZNTL icon
21
Zentalis Pharmaceuticals
ZNTL
$364M
$3.36M 1.14%
+77,500
New +$3.34M
HZNP
22
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$3.22M 1.09%
35,000
-10,000
-22% -$844K
MREO
23
Mereo BioPharma
MREO
$49.5M
$3.03M 1.03%
900,000
+275,000
+44% +$972K
MSACU
24
DELISTED
Medicus Sciences Acquisition Corp. Unit
MSACU
$2.96M 1%
+300,000
New +$3.05M
CRIS icon
25
CALL
Curis
CRIS
$9.02M
$2.83M 0.96%
+625
New +$2.61M
1
2 3 4

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q1 2021 Portfolio in Review

As of Q1 2021, Affinity Asset Advisors held 91 positions worth $294M, up 56% from $189M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Affinity Asset Advisors deployed $106M of net new capital in Q1 2021, opening 29 new positions and adding to 26 existing holdings. Its largest new stake was ARYA Sciences Acquisition Corp IV Class A Odinary Shares: 700,000 shares worth $7.33M.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 81% a quarter earlier, followed by Financials and Consumer Staples.

On the sell side, the largest reduction was Curis, an estimated $4.71M trimmed.

  • Affinity Asset Advisors's largest Q1 2021 buy was ARYA Sciences Acquisition Corp IV Class A Odinary Shares: 700,000 shares worth $7.33M.
  • Affinity Asset Advisors added most to BridgeBio Pharma in Q1 2021, an estimated $27.6M increase.
  • Affinity Asset Advisors's biggest Q1 2021 reduction was Curis, cutting an estimated $4.71M.
  • Affinity Asset Advisors fully exited Eidos Therapeutics, Inc. Common Stock in Q1 2021, selling an estimated $29.6M.
  • Affinity Asset Advisors's ten largest holdings make up 59% of its $294M portfolio in Q1 2021.
  • Affinity Asset Advisors opened 29 new positions and closed 19 in Q1 2021.
  • Affinity Asset Advisors's portfolio value rose 56% quarter-over-quarter to $294M.

Based on Affinity Asset Advisors's 13F filing for Q1 2021, filed 14 May 2021.